With a new measurement imminent, the Courier explores the experimental results and theoretical calculations used to predict ...
The FDA has cleared Magstim Horizon 3.0 TMS Therapy System as an adjunct for the treatment of MDD in adolescent patients aged 15 to 21 years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback